← Search & browse all drugs
DERMATOLOGICALS › CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS › CORTICOSTEROIDS, PLAIN › Corticosteroids, potent (group III)
fluocinonide
D07AC08
Forms & Strengths
- Cream: 0.05%
- Ointment: 0.05%
- Gel: 0.05%
- Solution: 0.05%
Adult Dosing
- Apply thin film to affected area 2 to 4 times daily depending on severity
- Limit treatment to 2 consecutive weeks
- Maximum weekly dose should not exceed 60 grams
Pediatric Dosing
- Children < 12 years: Safety and efficacy not established
- Children >= 12 years: Apply sparingly 2 times daily for up to 2 weeks
- Avoid use in the diaper area
Indications
- Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Plaque psoriasis
- Atopic dermatitis
- Contact dermatitis
Mechanism of Action
- High-potency topical corticosteroid
- Induces phospholipase A2 inhibitory proteins (lipocortins)
- Controls biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes
- Decreases inflammation, relieves pruritus, and constricts blood vessels
Contraindications
- Hypersensitivity to fluocinonide or any component of the formulation
- Viral skin infections (e.g., varicella, herpes simplex)
- Fungal or bacterial skin infections without concurrent anti-infective therapy
- Rosacea and perioral dermatitis
Adverse Reactions
- Burning, stinging, and irritation at application site
- Pruritus and dry skin
- Folliculitis and acneiform eruptions
- Skin atrophy, striae, and telangiectasia
- Hypopigmentation
- Systemic effects from excessive absorption: HPA axis suppression, Cushing's syndrome, hyperglycemia
Drug Interactions
- Strong CYP3A4 inhibitors (may increase systemic absorption if used concurrently with systemic corticosteroids)
- Other topical corticosteroids (increased risk of systemic toxicity)
- Local immunosuppressants
Curated Content: Needs Vetting Before Put to Clinical Use